Replacing the Animal Component in SerumEvaluating Raw Materials for Inclusion in Optimized Hybridoma Media

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-09-02-2001
Volume 25
Issue 9

With the scarcity of CGMP facilities spurring a production crisis, manufacturers need to optimize their processes and formulations for individual hybridoma cell lines and production systems.

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Drug Digest: Focusing on Solid Dosage Trends and Demand
Behind the Headlines, episode 7
Related Content